SIO CAPITAL MANAGEMENT LLC
Q1 2024 Form 13-F
NEW YORK, NEW YORK
CIK 0001482416
· CRD 165989
· SEC-registered investment adviser
$335.8M Reported Value Total
SIO CAPITAL MANAGEMENT, LLC reports 7 total accounts under management (AUM). There are 7 discretionary accounts valued at $1,405,889,917, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
6 funds
· $864.7M gross asset value
Hedge Fund: $864.7M
Source: Form ADV filed 2026-03-18
Reported value
$335.8M
Quarter over quarter
+14.2%
Holdings
48
Top-10 concentration
58.6%
Key People
Form ADV owners & control persons
Michael Bernard Castor
MANAGING MEMBER
Judah Zvi Drillick
CHIEF EXECUTIVE OFFICER
Jin Woo Lee
CHIEF COMPLIANCE OFFICER
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q1 2024 13F record
Q1 2024 13F filing summary
| Period of report | March 31, 2024 |
|---|---|
| Filed | May 15, 2024 |
| Form | 13F-HR |
| Reported value | $335.8M |
| Positions | 48 |
| Change in reported value | -23.5% |
| New positions | 21 |
| Exited positions | 12 |
| Position turnover | 55.0% |
| Top-10 concentration | 58.6% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
51 | $528.5M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
57 | $604.3M |
|
Q1 2026 13F
Filed May 14, 2026
|
73 | $697.3M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
65 | $635.7M |
|
Q3 2025 13F
Filed Nov 13, 2025
|
51 | $395.2M |
|
Q2 2025 13F
Filed Aug 13, 2025
|
49 | $261.8M |
|
Q1 2025 13F
Filed May 15, 2025
|
53 | $335.8M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
51 | $355.4M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
38 | $252.2M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
46 | $369.5M |
|
Q1 2024 13F
Filed May 15, 2024
|
48 | $335.8M |
|
Q4 2023 13F
Filed Feb 13, 2024
|
39 | $439.2M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
52 | $323.1M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
41 | $393.2M |
|
Q1 2023 13F
Filed May 12, 2023
|
44 | $202.3M |
|
Q4 2022 13F
Filed Feb 13, 2023
|
41 | $270.4M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
43 | $314.7M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
59 | $266.2M |
|
Q1 2022 13F
Filed May 16, 2022
|
61 | $302.3M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
67 | $331.7M |
28 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q1 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | LH LABORATORY CORPORATION OF AMERICA HOLDINGS | $49.4M | 14.69% |
| 2 | INSM P INSMED INC | $37.0M | 11.01% |
| 3 | CI CIGNA GROUP | $27.6M | 8.23% |
| 4 | GMED GLOBUS MEDICAL INC | $21.1M | 6.28% |
| 5 | MDGL MADRIGAL PHARMACEUTICALS INC | $13.6M | 4.06% |
| 6 | GSK GSK PLC | $11.3M | 3.36% |
| 7 | ZBH ZIMMER BIOMET HOLDINGS INC | $9.8M | 2.92% |
| 8 | MDT MEDTRONIC PLC | $9.2M | 2.72% |
| 9 | OGN ORGANON & CO | $9.0M | 2.68% |
| 10 | TYRA TYRA BIOSCIENCES INC | $8.8M | 2.62% |
| 11 | IRWD P IRONWOOD PHARMACEUTICALS INC | $8.5M | 2.52% |
| 12 | EMBC EMBECTA CORP | $7.8M | 2.31% |
| 13 | TFX TELEFLEX INCORPORATED | $7.7M | 2.28% |
| 14 | ARQT ARCUTIS BIOTHERAPEUTICS INC | $6.3M | 1.88% |
| 15 | BBIO BRIDGEBIO PHARMA INC | $6.3M | 1.87% |
| 16 | HUMA HUMACYTE INC | $6.2M | 1.85% |
| 17 | ANIP ANI PHARMACEUTICALS INC | $6.0M | 1.8% |
| 18 | ATXS ASTRIA THERAPEUTICS INC | $5.8M | 1.72% |
| 19 | SPRY ARS PHARMACEUTICALS INC | $5.5M | 1.63% |
| 20 | HCSG HEALTHCARE SERVICES GROUP INC | $5.3M | 1.57% |
Values as reported on the Q1 2024 Form 13F. Every position is in the holdings table below.